V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

CRISPR Therapeutics AG Executive Compensation (FY25)

CRSP · Executive and director compensation, fiscal 2023 to 2025
Data as of September 7, 2026Latest filing (8-K): June 4, 2026
215 figures on this page: 209 cited to the filing that reported them, 6 calculated from figures it prints. See the citations
Samarth Kulkarni, Chairman and Chief Executive Officer, received $7,678,477 in total compensation for fiscal 2025, and Kulkarni's total moved 76.9% lower from the $33,175,626 reported for fiscal 2024. The disclosed chief executive pay ratio for fiscal 2025 is 26:1, against median employee compensation of $295,181. Shareholders supported the say-on-pay proposal with 69.4% of votes cast for or against in favor at the meeting held June 4, 2026 for fiscal 2025. The disclosed peer group includes Apellis Pharmaceuticals, Arrowhead Pharmaceuticals, Avidity Biosciences, Beam Therapeutics and Blueprint Medicines, among others.
Chief executive, fiscal 2025
◇
Samarth Kulkarni
Latest say-on-pay support
=
June 4, 2026
Chief executive pay ratio
◇
To the median employee
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Samarth Kulkarni: $33,175,626 → $7,678,477 (76.9% lower)
Say-on-pay support: 79.7% → 69.4% (10.3 points lower)
CEO pay ratio: 121:1 → 26:1 (78.5% lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is CRISPR Therapeutics AG's chief executive and what were they paid?
Samarth Kulkarni, Chairman and Chief Executive Officer, received $7,678,477 in total compensation for fiscal 2025. Kulkarni's total moved 76.9% lower from the $33,175,626 reported for fiscal 2024.
What was CRISPR Therapeutics AG's say-on-pay result?
Shareholders supported the say-on-pay proposal with 69.4% of votes cast for or against in favor at the meeting held June 4, 2026 for fiscal 2025.
Which companies are in CRISPR Therapeutics AG's peer group?
The disclosed peer group includes Apellis Pharmaceuticals, Arrowhead Pharmaceuticals, Avidity Biosciences, Beam Therapeutics and Blueprint Medicines, among others.
What is CRISPR Therapeutics AG's chief executive pay ratio?
The disclosed chief executive pay ratio for fiscal 2025 is 26:1, against median employee compensation of $295,181.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Samarth Kulkarni
Chairman and Chief Executive Officer
◇—◇◇◇—◇◇
Raju Prasad
Chief Financial Officer
◇◇◇◇◇—◇◇
James Kasinger
General Counsel
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Samarth Kulkarni
Chairman and Chief Executive Officer
◇—◇◇◇—◇◇
Naimish Patel
Chief Medical Officer
◇◇◇◇◇—◇◇
James Kasinger
General Counsel
◇—◇◇◇—◇◇
Raju Prasad
Chief Financial Officer
◇—◇◇◇—◇◇
Julianne Bruno
Former Chief Operating Officer
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Samarth Kulkarni
Chairman and Chief Executive Officer
◇—◇◇◇—◇◇
Naimish Patel
Chief Medical Officer
◇—◇◇◇—◇◇
Julianne Bruno
Former Chief Operating Officer
Departed during or after this year
◇—◇◇——◇◇
Raju Prasad
Chief Financial Officer
◇—◇◇◇—◇◇
James Kasinger
General Counsel and Secretary
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
James R. KasingerOPTION◇——◇—◇◇
James R. KasingerRSU◇——◇——◇
Julianne BrunoOPTION◇——◇—◇◇
Julianne BrunoRSU◇——◇——◇
Naimish PatelRSU◇——◇——◇
Naimish PatelRSU◇——◇——◇
Naimish PatelOPTION◇——◇—◇◇
Raju PrasadRSU◇——◇——◇
Raju PrasadRSU◇——◇——◇
Raju PrasadOPTION◇——◇—◇◇
Samarth KulkarniOPTION◇——◇—◇◇
Samarth KulkarniRSU◇——◇——◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
James KasingerPSU◇◇——
PSU◇◇——
PSU◇◇——
Raju PrasadPSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
Samarth KulkarniPSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
Naimish PatelPSU◇◇——
PSU◇◇——
PSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Douglas A. Treco
Lead independent director
◇—◇———◇
John T. Greene
◇—◇———◇
Katherine A. High
◇—◇———◇
Maria Fardis
◇—◇———◇
Ali Behbahani
◇—◇———◇
H. Edward Fleming, Jr
◇—◇———◇
Simeon J. George
◇—◇———◇
Briggs W. Morrison
◇—◇——◇◇
Christian Rommel
◇—◇———◇
Samarth Kulkarni and Sandesh Mahatme served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board chair premium◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Apellis Pharmaceuticals APLS
  • Arrowhead Pharmaceuticals ARWR
  • Avidity Biosciences RNAM
  • Beam Therapeutics BEAM
  • Blueprint Medicines BPMC
  • BridgeBio Pharma BBIO
  • Cytokinetics CYTK
  • Denali Therapeutics DNLI
  • Dyne Therapeutics DYN
  • Intellia Therapeutics NTLA
  • Ionis Pharmaceuticals IONS
  • Legend Biotech LEGN
  • Neurocrine Biosciences NBIX
  • Prothena PRTA
  • Revolution Medicines RVMD
  • Sarepta Therapeutics SRPT
  • Ultragenyx Pharmaceutical RARE
  • Vaxcyte PCVX
  • Vir Biotechnology VIR

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 4, 2026=◇◇◇
2024June 5, 2025=◇◇◇
2023May 30, 2024=◇◇◇
2021June 9, 2022=◇◇◇
2020June 10, 2021=◇◇◇
2017May 30, 2018=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when CRISPR Therapeutics AG files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact CRISPR Therapeutics AG disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where CRISPR Therapeutics AG sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Say-on-pay responsiveness
CRISPR Therapeutics AG recorded a low support level. The responsiveness analysis covers what the company said it would do, what it did, and how that compares with the companies that recovered their vote.
Responsiveness analysis
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether CRISPR Therapeutics AG's disclosed peer group is defensible, who names CRISPR Therapeutics AG back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
215 figures on this page: 209 cited to the filing that reported them, 6 calculated from figures it prints.
209 cited to the filing
6 calculated from the filing

Documents cited

  1. 0001193125-26-257593
    Item 5.07. Submission of Matters to a Vote of Security Holders
  2. 0001193125-26-165158
    CEO Pay Ratio · DIRECTOR COMPENSATION · Grants of Plan-Based Awards for Fiscal Year 2025 · Outstanding Equity Awards at Fiscal Year-End · and 1 more section
  3. 0000950170-25-083799
  4. 0000950170-25-054711
    Summary Compensation Table
  5. 0000950170-24-067660
  6. 0000950170-24-043025
    Summary Compensation Table
  7. 0000950170-22-011570
  8. 0001564590-21-032800
  9. 0001193125-18-181922
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “CRISPR Therapeutics AG executive compensation, FY2023–FY2025.” https://intel.velarion.ai/comp/CRSP (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about CRISPR Therapeutics AG and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers CRISPR Therapeutics AG discloses

The companies named in CRSP's own disclosed peer group.

Apellis PharmaceuticalsArrowhead PharmaceuticalsBeam TherapeuticsBridgeBio PharmaCytokineticsDenali TherapeuticsDyne TherapeuticsIonis PharmaceuticalsNeurocrine BiosciencesSarepta TherapeuticsUltragenyx PharmaceuticalVaxcyte

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  The Pay Desk · Methodology · Terms · Privacy